An alternative route to pertussis protection?

[...]the relative efficacy of BPZE1 versus Tdap against clinical pertussis is unclear, because no antibody correlate of protection has been established. [...]we agree with the authors' assessment that BPZE1 could help to avert B pertussis infections, and could lead to reduced transmission and diminished epidemic cycles, but more studies are required to ensure the durability of the immune response and to establish whether BPZE1's less robust humoral response impairs the vaccine's disease prevention. KME has received grants from the US National Institutes of Health (mentoring young investigators) and the Centers for Disease Control and Prevention (assessing vaccine safety), has consulted for Bionet and IBM, and has served on data safety and monitoring boards for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche.